Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited Listed on the ASX and Nasdaq under the ticker TLX. You are encouraged to report negative side effects of prescription drugs to the FDA.

Telix is a global biopharmaceutical company focused on developing and commercializing radiopharmaceuticals to address significant unmet medical need in oncology and rare diseases. Telix is a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations

in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing [email protected]. Please see full Illuccix Prescribing Information:https://illuccixhcp.com/wp-content/uploads/illuccix-prescribing-information.pdf

01/09/2026

Enrollment is now complete in the Phase 3 BiPASS™ study evaluating Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) for prostate cancer imaging in the pre-biopsy setting.

Telix has also positively engaged with the U.S. FDA on a New Drug Application (NDA) pathway that would support new product reimbursement and broaden patient access to ⁶⁸Ga-PSMA-PET imaging.

BiPASS is the first registrational study of ⁶⁸Ga-PSMA-PET imaging before biopsy. The study aims to evaluate whether combining MRI with Telix’s proprietary ⁶⁸Ga-PSMA-PET agents can improve diagnostic accuracy, reduce unnecessary biopsies or improve biopsy targeting compared with current standard practice.

A sincere thank you to the investigators, study teams and, most importantly, the 350 patients who participated in this important research.

Read more on our website here: https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/

ClinicalTrials.gov ID: NCT07052214

01/09/2026

September is Prostate Cancer Awareness Month.

There is no single path through prostate cancer. From early detection, to diagnosis, treatment and ongoing care, every man’s journey is different.

At Telix, we’re committed to helping advance prostate cancer care through innovation in precision medicine and targeted therapies, with the goal of enabling more informed and personalized approaches across the patient journey.

Throughout September, we’ll be sharing information, perspectives and practical resources to help people think about the different elements that can shape their own approach to prostate cancer care.

Build your blueprint. Start the conversation.

Learn more about Telix’s focus on prostate cancer here: https://telixpharma.com/urologic-oncology/

Telix has appointed David Gill as Chair of the Board.David joined Telix as a Non-Executive Director in May 2026 as part ...
31/08/2026

Telix has appointed David Gill as Chair of the Board.

David joined Telix as a Non-Executive Director in May 2026 as part of the Company’s Board expansion and succession planning. He brings more than 35 years of global life sciences experience including in radiopharmaceuticals, with deep expertise in capital markets, scaling businesses and corporate governance.

We thank Mark Nelson for his leadership as interim Chair and look forward to his continued contribution as a Non-Executive Director.

Read the announcement here: https://telixpharma.com/news-views/telix-appoints-david-gill-as-chair/

19/08/2026

Telix has released its results for the half-year ended June 30, 2026.

H1 2026 delivered strong commercial performance, with revenue increasing 22% year-over-year to US$477 million.

Continued investment in R&D, manufacturing and supply chain capabilities is supporting Telix’s next phase of growth and driving significant progress across the Company’s late-stage and next generation pipeline.

To learn more about the results, visit our website, where you can also register for today’s H1 2026 investor webcast: https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/

18/08/2026

Radioisotopes are all around us. They're found naturally in the environment and even in the food we eat.

But only a select few have the properties needed to be used safely and effectively for medical imaging.

In the first episode of Radiopharma Unpacked, nuclear medicine radiologist Dr. Umesh Oza explains what radioisotopes are, why only certain ones are suitable for positron emission tomography (PET) imaging, and how they make this powerful imaging technology possible.

Watch the full episode here: https://www.youtube.com/watch?v=vqTanq7bljg

12/08/2026

In PET/CT imaging, half-life is only half the story.

How an isotope is produced is just as important, influencing where it can be made, how far it can travel, and how flexibly it can fit into clinical workflows.

In this episode of Radiopharma Unpacked, nuclear medicine radiologist Dr. Umesh Oza explains why half-life and production need to be considered together when choosing an isotope for positron emission tomography (PET) imaging.

Watch the full episode here: https://www.youtube.com/watch?v=vqTanq7bljg

05/08/2026

Choosing the right radioisotope for PSMA-PET/CT imaging is about balancing imaging performance with real-world usability.

In this episode of Radiopharma Unpacked, Dr. Umesh Oza explains why, for his practice, gallium-68 strikes that balance, and how choosing a radioisotope means looking beyond any single characteristic.

Watch the full episode here: https://www.youtube.com/watch?v=vqTanq7bljg

Institutional investors and analysts are invited to join us in New York City for the 2026 Telix R&D Day on September 22....
05/08/2026

Institutional investors and analysts are invited to join us in New York City for the 2026 Telix R&D Day on September 22.

Members of the Telix leadership team and key opinion leaders will share the latest scientific, clinical and strategic developments across our therapeutic and precision medicine pipeline.

We also look forward to hosting our Capital Markets Day in Melbourne on November 4, 2026, with further details to be announced separately.

Learn more and register: https://telixpharma.com/news-views/telix-to-host-rd-day-in-new-york-city-on-september-22-2026/

31/07/2026

Why does positron yield matter?

Positron yield is one of the key properties that differentiates PET radioisotopes, with implications for image quality, clinical workflow and the patient experience.

In this episode of Radiopharma Unpacked, nuclear medicine radiologist Dr. Umesh Oza explains why.

Watch the full episode here: https://youtu.be/vqTanq7bljg?si=Jp_A_QFTyVeBkjBk

Address

55 Flemington Road, North
Melbourne, VIC
3051

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Website

Alerts

Be the first to know and let us send you an email when Telix Pharmaceuticals Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category